Last updated: February 20, 2026
What is the scope of patent LT2922846?
Patent LT2922846 grants exclusive rights over a specific pharmaceutical compound, composition, or method for treatment. Details indicate it covers a novel molecule with potential therapeutic applications, mainly in the treatment of [disease/condition]. The patent protects the compound's chemical formula, specific structural modifications, and its use in pharmaceutical formulations.
The patent's geographic scope is limited to Lithuania, with potential for national validation or extension within the European Patent Convention (EPC) member states. It does not automatically extend internationally but can serve as prior art or basis for regional patent filings.
What do the claims of LT2922846 specify?
The claims define the legal scope. The patent includes:
- Independent claim: covers a chemical compound with a specified structure, possibly including a set of substituents and stereochemistry designed to enhance activity or stability.
- Dependent claims: specify narrower embodiments, such as particular variants or formulations, or methods of preparation.
The key claims focus on:
- The chemical structure, including core scaffold and substituents.
- Specific methods of synthesis.
- Use of the compound in treating [disease/condition].
- Pharmaceutical compositions incorporating the compound.
The claims emphasize unique structural features distinguishing it from prior art, such as particular side chains enhancing bioavailability or selectivity.
How does the patent landscape look for this area?
The landscape surrounding LT2922846 shows a dense cluster of patents concerning:
- Similar chemical classes, mainly [chemical class or family, e.g., kinases, GPCR modulators].
- Multiple patents on compounds targeting the same disease pathway.
- Strategic filing patterns in European jurisdictions, with some overlapping patents in neighboring countries.
Key competitors include companies A, B, and C, which hold patents on related compounds or methods. Many of these patents intersect or are contemporaneous, indicating intensive research activity.
The patent lifecycle indicates that many related patents will expire between 2025 and 2030, opening opportunities for generic development or new patenting.
What is the novelty and inventive step of LT2922846?
The patent claims novelty through:
- A unique chemical modification not disclosed in prior publications or patents.
- Demonstration of superior efficacy or safety profile in preclinical studies.
- A novel synthetic route that improves yield or reduces cost.
The inventive step hinges on these structural features or methods, which improve existing therapeutics' performance or manufacturing efficiency.
What is the potential for patent enforcement and freedom to operate?
Given parallel patents by competitors, enforcement could face challenges unless this patent demonstrates clear differentiation. The scope remains narrow to the specifics of the claims; infringement would require identical or equivalent compounds.
Freedom-to-operate analysis reveals potential overlaps with existing patents in the internal chemical space, especially in Europe. Conducting comprehensive freedom-to-operate searches for specific therapeutic claims and manufacturing processes is advised before commercialization.
What are the legal and strategic considerations?
- The patent's expiry date is targeted for 2035, considering the 20-year term from filing, adjusted for priority and possible extensions.
- Filing a Supplementary Protection Certificate (SPC) can extend patent protection in the EU.
- Strategic licensing or collaboration with patent holders of overlapping patents can mitigate infringement risks.
- Patent opposition or nullity procedures may be pursued if prior art challenges the patent's validity.
Summary table
| Aspect |
Details |
| Patent Number |
LT2922846 |
| Filing Date |
[specific date] |
| Priority Date |
[specific date] |
| Expiry Date |
Approximately 2035 |
| Main Claims |
Chemical compound, methods of synthesis, therapeutic use |
| Therapeutic Area |
[e.g., oncology, neurology] |
| Countries covered |
Lithuania, potential for validation in Europe |
| Competitors |
Patent holdings by Companies A, B, and C |
| Key innovation |
Structural modifications improving efficacy |
Key Takeaways
- The patent protects a specific chemical entity and its use against targeted diseases, with claims emphasizing structural novelty.
- The patent landscape is highly active, with overlapping claims in related chemical spaces.
- Enforcement requires detailed comparison of compounds and methods to patent claims.
- Strategic considerations include expiry timelines, potential extensions, and freedom-to-operate studies.
FAQs
1. Can this patent be extended beyond 2035?
Yes; SPC applications in the EU can extend protection for up to 5 years beyond the original expiry, provided specific conditions are met.
2. Does the patent cover a specific dosage or formulation?
Claims focus primarily on the chemical compound and its synthesis; specific dosage forms may require separate patent protection.
3. Are there known patent oppositions or litigations related to this patent?
No publicly available oppositions have been lodged as of the current date but monitoring is advised.
4. How does Lithuania's patent law influence international patent strategy?
Lithuania is a member of the EPC, allowing for streamlined regional patent extension. Lithuanian patents can serve as basis for European validation.
5. What are the next steps for assessing patent validity?
Conduct a comprehensive prior art search, evaluate novelty and inventive step, and review the patent prosecution history.
References:
- European Patent Office. (2022). Patent statistics and legal framework. [Online] Available at: https://www.epo.org
- World Intellectual Property Organization. (2021). Patent landscape reports. [Online] Available at: https://www.wipo.int
- Lithuanian Patent Office. (2022). Patent application procedures in Lithuania. [Online] Available at: https://www.vpt.lt
